GlassScriptPhysician profile
Brian A Honbo
NPI 1578587721
$680.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $60.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219.54 | 2019 | |
| Pfizer INC. | $186.05 | 2019-2020 | |
| Novo Nordisk INC | $70.67 | 2019 | |
| Intercept Pharmaceuticals, INC. | $25.87 | 2019 | |
| Merck Sharp & Dohme LLC | $24.64 | 2019-2020 | |
| Daiichi Sankyo INC. | $23.92 | 2019 | |
| Genentech USA, INC. | $22.99 | 2019 | |
| Amgen INC. | $19.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.95 | 2019 | |
| Lilly USA, LLC | $16.79 | 2019 | |
| Abbvie INC. | $16.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.92 | 2019 | |
| Boston Scientific Corporation | $11.42 | 2019 | |
| Astellas Pharma US INC | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Honbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.